Research Topics
Species | Charles E GeyerSummaryAffiliation: Allegheny General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Lapatinib plus capecitabine for HER2-positive advanced breast cancerCharles E Geyer
Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA 15212, USA
N Engl J Med 355:2733-43. 2006..In this trial, we compared lapatinib plus capecitabine with capecitabine alone in such patients...- Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Priya Rastogi
University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
J Clin Oncol 26:778-85. 2008..Protocol B-27 was designed to determine the effect of adding docetaxel (T) to preoperative AC on tumor response rates, DFS, and OS... - Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupPriya Rastogi
National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, Pittsburgh, PA 15212, USA
Clin Breast Cancer 11:228-34. 2011..The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally advanced breast cancer (LABC)... - Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trialPatricia A Ganz
National Surgical Adjuvant Breast and Bowel Project Operations Center NSABP, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
J Clin Oncol 29:1110-6. 2011..The National Surgical Adjuvant Breast and Bowel Project B-30 trial included menstrual history (MH) and quality-of-life (QOL) studies to compare treatments on these outcomes... - Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Gong Tang
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, and Pathology Division, Pittsburgh, PA, USA
Breast Cancer Res Treat 127:133-42. 2011..219) or DFS (P = 0.099). Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combining RS and Adjuvant!. RS should be used for estimating relative chemotherapy benefit... - Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancerChungyeul Kim
National Surgical Adjuvant Breast and Bowel Project, Division of Pathology, 1307 Federal St, Pittsburgh, PA 15212, USA
J Clin Oncol 29:4160-7. 2011..We used gene expression profiling and ER protein assays to help elucidate molecular mechanism(s) responsible for tamoxifen resistance in breast tumors... - Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerSoonmyung Paik
Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
J Clin Oncol 24:3726-34. 2006..The relationship between the RS and chemotherapy benefit is not known... - The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel ProjectD Lawrence Wickerham
NSABP Operations Office, Biostatistical Center and Graduate School of Public Health, University of Pittsburgh, and Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
Semin Oncol 35:522-9. 2008.... - Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancerStewart J Anderson
Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
J Clin Oncol 27:2466-73. 2009..Locoregional failure (LRF) after breast-conserving therapy (BCT) is associated with increased risk of distant disease and death. The magnitude of this risk has not been adequately characterized in patients with lymph node-negative disease... - A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37Irene L Wapnir
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
Clin Breast Cancer 8:287-92. 2008..Although multidrug regimens are preferred, the agents, doses, and use of supportive therapy are at the discretion of the investigator... - Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancerBushra Haq
Western Pennsylvania Hospital, The Western Pennsylvania Cancer Institute, Pittsburgh, PA 15224, USA
Womens Health (Lond Engl) 5:135-47. 2009..Concerns regarding cardiac safety and mechanisms of resistance to trastuzumab remain important issues and are being addressed in ongoing research efforts... - The emerging role of lapatinib in HER2-positive breast cancerAlice Ulhoa-Cintra
Department of Human Oncology, Allegheny General Hospital, Allegheny Cancer Center, Fifth Floor, 320 East North Avenue, Pittsburgh, PA 15212, USA
Curr Oncol Rep 10:10-7. 2008..This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease... - Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trialsIrene L Wapnir
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
J Clin Oncol 24:2028-37. 2006..Locoregional failure after breast-conserving surgery is associated with increased risk of distant disease and death. The magnitude of this risk in patients receiving chemotherapy has not been adequately characterized... - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H Romond
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
N Engl J Med 353:1673-84. 2005..CONCLUSIONS: Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.).. - Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27Harry D Bear
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
J Clin Oncol 24:2019-27. 2006..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)... - Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research ProgramJames N Atkins
National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15212, USA
Clin Colorectal Cancer 5:181-7. 2005..CONCLUSION: This regimen of pemetrexed and oxaliplatin has activity in advanced colorectal cancer, and the toxicity profile suggests that escalation of the dose of pemetrexed in this combination may be possible... - Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast canElizabeth Tan-Chiu
National Surgical Adjuvant Breast and Bowel Project (NSABP, University of Pittsburgh, PA, USA
J Clin Oncol 23:7811-9. 2005..CONCLUSION: Administering trastuzumab with paclitaxel after AC increases incidence of CHF and lesser CD. Potential cardiotoxicity should be carefully considered when discussing benefits and risks of this therapy... - Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research GroupJohn T Hamm
National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Philadelphia, PA, USA
Clin Breast Cancer 8:257-63. 2008..This trial also evaluated the feasibility of tissue collection for gene-expression profiling... - Anthracyclines in the treatment of HER2-negative breast cancerSoonmyung Paik
J Natl Cancer Inst 100:2-4. 2008 - Overcoming treatment challenges in advanced breast cancerBarbara Harkins
Protocol Development and Management, National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburg, PA 15212 5234, USA
Semin Oncol Nurs 23:S10-6. 2007..To describe new clinical findings, efficacy, and safety regarding the use of targeted agents in the treatment of HER2-positive metastatic breast cancer... - A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancerSheri K Dennison
Walter Reed Army Medical Center, 6900 Georgia Ave NW, Washington, DC 20307, USA
Invest New Drugs 25:545-51. 2007..The combination of gefitinib and docetaxel is an active regimen in patients with previously untreated metastatic breast cancer, with a clinical benefit rate and toxicity profile in the range of that reported for docetaxel alone... - Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancerEleftherios P Mamounas
Cancer Center, Aultman Health Foundation, Canton, OH 44710, USA
Clin Breast Cancer 4:S121-6. 2004..These trials will be important in establishing a role for this agent in the adjuvant setting and will hopefully lead to the development of more effective adjuvant chemotherapy regimens in the future... - Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trialEleftherios P Mamounas
Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
J Clin Oncol 26:1965-71. 2008.... - Trastuzumab for early breast cancerJohn Bryant
Lancet 367:728. 2006